Insmed Reports Phase 2b CEDAR Study of Brensocatib in CRSsNP Did Not Meet Primary Endpoint

Insmed Incorporated has released an update on its Phase 2b CEDAR study, which is evaluating the safety and efficacy of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP). The company announced that the trial did not meet its primary endpoint of a statistically significant reduction in the mean composite score of three cardinal symptoms associated with CRSsNP when compared to a placebo.

The CEDAR study involved 300 participants who were randomized to receive either brensocatib or a placebo over a 24-week treatment period. While the primary endpoint was not achieved, Insmed noted that secondary endpoints, including measures of individual symptom improvement and quality-of-life assessments, showed trends favoring brensocatib. The company stated that it will further analyze the data to determine next steps for the development of brensocatib in this indication. Additional details regarding the trial results are expected to be shared at upcoming medical conferences or through peer-reviewed publications.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI